Last checked at 3 Jun 2011 07:00
3 June 2011 Scancell Holdings Plc (`Scancell Holdings' or the `Company') Appointment of Broker
Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines is pleased to announce the appointment of XCAP Securities plc as Broker, with immediate effect.
For further information contact:
Scancell Holdings plc Tel: +44 (0) 207 245 1100 Professor Lindy Durrant www.scancell.com Zeus Capital Tel: +44 (0) 161 831 1512 Nominated Advisor Ross Andrews/ Tom Rowley XCAP Securities plc Tel: +44 (0)20 7101 7070 Broker John Belliss / Parimal Kumar Hansard Communications Ltd Tel: +44 (0)20 7245 1100 Adam Reynolds / Guy McDougall About ScancellScancell is developing novel therapeutic vaccines for the treatment of cancerand infectious diseases based on its groundbreaking ImmunoBody® technologyplatform. Scancell's first cancer vaccine SCIB1, which entered clinical trialsin 2010, is being developed for the treatment of melanoma.Treating cancer by vaccination allows small non-toxic doses of a vaccine to beadministered to a patient, stimulating an immune response. Effective cancervaccines need to target dendritic cells to stimulate both parts of the cellularimmune system; the helper cell system where inflammation is stimulated at thetumour site; and the cytotoxic T-lymphocyte or CTL response where immune systemcells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.
An ImmunoBody® is a human antibody or fusion protein engineered to expresshelper cell and CTL epitopes from tumour antigens over-expressed by cancercells. Antibodies are ideal vectors for carrying T cell epitopes from tumourantigens as they have long half-lives and can effectively target dendriticcells via their Fc receptors, allowing efficient stimulation of both helper andCTL responses.The Immunobody® technology can be adapted to provide the basis for treating anytumour type and may also be of potential utility in the development of vaccinesagainst hepatitis, HIV and other chronic infectious diseases.
vendor